← Back to DRTS filing summaryOriginal filing text · Part I
Item 11 — Quantitative and Qualitative Disclosures About Market Risk
Alpha Tau Medical Ltd. · 20-F · FY 2025 · Period ended Dec 31, 2025
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
about Market Risk
We are exposed to market risk
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates and interest
rates, which are discussed in detail below.
Foreign currency risk
Our financial results are
reported in U.S. dollars, changes in exchange rate between the USD and local currencies in those countries in which we operate (primarily
the NIS) may affect the results of our operations. The USD cost of our operations in countries other than the United States, is negatively
influenced by revaluation of the USD against other currencies.
During 2025, the value of
the U.S. dollar strengthened against the NIS by approximately 12.5%. Our most significant foreign currency exposures are related to our
operations in Israel.
With respect to our foreign currency
exposures for the years ended December 31, 2024 and 2025, a 10% unfavorable movement in foreign currency exchange rates would have increased
our operating expenses by approximately 4.7% and 5.6%, respectively.
Other Market Risks
We do not believe that we
have material exposure to interest rate risk due to the fact that we have no long-term debt other than our $6,352 loan from Bank Leumi
Le-Israel BM in connection with the acquisition of a long-term leasehold on a plot of land in Jerusalem.
We do not believe that we
have any material exposure to inflationary risks. We do not believe that the rate of inflation in Israel has had a material impact on
our business to date. However, our costs in Israel may increase if inflation in Israel exceeds the devaluation of the shekel against the
U.S. dollar (to the extent that it devalues at all) or if the timing of such devaluation lags behind inflation in Israel.